Voyager milestones and biotech advances highlighted in recent reports

Voyager 1 is set to be one light‑day from Earth in November 2026, a distance that will make two‑day round‑trip communications the new norm for the probe [1]. In a separate development, biotechnology firm Voyager Therapeutics announced that the U.S. Food and Drug Administration has cleared its investigational new drug application for VY1706, a gene‑therapy aimed at reducing tau protein in early Alzheimer’s disease [2].

Key takeaways

• Voyager 1 will reach a distance of one light‑day (≈16 billion miles) from Earth in November 2026 [1].
• Signals to Voyager 1 travel at light speed, so a command sent on a Monday will be answered on Wednesday [1].
• The probe transmits data at about 160 bits per second, requiring multiple antenna arrays to receive its faint signal [1].
• Voyager Therapeutics received FDA IND clearance for VY1706, enabling a multi‑site clinical trial to begin in the second half of 2026 [2].
• Preclinical studies show VY1706 can reduce tau protein by up to 75 % in key brain regions, with a favorable safety profile in non‑human primates [2].

Voyager 1 reaches a historic distance

Launched in 1977, Voyager 1 has been cruising away from Earth at roughly 38,000 mph since its Saturn flyby in 1980 [1]. By November 2026, the spacecraft will be about 16 billion miles away, a distance that requires 24 hours for a light‑speed signal to arrive. Project manager Suzy Dodd explained that this “one light‑day” milestone means any command sent to the probe will be answered a full day later, effectively turning a Monday greeting into a Wednesday response [1]. The probe’s data rate remains extremely low—about 160 bits per second—so NASA relies on multiple Deep Space Network antenna arrays to capture the weak transmissions [1]. Despite these challenges, the team plans to keep essential instruments like the magnetometer and plasma wave subsystems operational as the probe approaches its 50th anniversary in 2027 [1].

Voyager Therapeutics advances gene‑therapy for Alzheimer’s

In a separate sector, Voyager Therapeutics announced that the FDA has cleared its IND application for VY1706, marking the first gene‑therapy to target tau protein in Alzheimer’s disease [2]. The therapy uses a vectorized siRNA encapsulated in a proprietary AAV capsid to deliver the payload intravenously, aiming to reduce both intracellular and extracellular tau [2]. Preclinical data across mouse and non‑human primate models showed dose‑dependent reductions of MAP T mRNA by 51‑75 % and tau protein by 48‑64 % in regions such as the entorhinal cortex and hippocampus [2]. The upcoming trial will enroll up to 18 participants across three dose cohorts, with the primary focus on safety and tolerability [2].

Why it matters

Voyager 1’s approach to a one‑light‑day distance underscores the engineering longevity of a mission launched nearly five decades ago, offering a unique window into the heliopause and interstellar space as it continues to operate with limited power and instrumentation [1]. Meanwhile, Voyager Therapeutics’ IND clearance represents a potential shift in Alzheimer’s treatment, targeting tau—a protein increasingly recognized as a critical factor in disease progression—through a single intravenous gene‑therapy dose [2]. Both stories illustrate how the name “Voyager” spans distinct frontiers: one exploring the outer reaches of our solar system, the other probing molecular pathways to combat neurodegeneration.